Current status and progress of immunotherapy and targeted therapy for advanced biliary tract cancers
10.3760/cma.j.cn115610-20250509-00184
- VernacularTitle:晚期胆道恶性肿瘤免疫与靶向治疗的现状与进展
- Author:
Xiangcheng LI
1
;
Bin HUANG
1
;
Jiang CHANG
1
Author Information
1. 南京医科大学第一附属医院肝胆中心，南京 210029
- Publication Type:Journal Article
- Keywords:
Biliary tract neoplasms;
Chemotherapy;
Immunotherapy;
Targeted therapy;
Efficacy
- From:
Chinese Journal of Digestive Surgery
2025;24(7):832-839
- CountryChina
- Language:Chinese
-
Abstract:
Biliary tract cancers comprise a spectrum of invasive tumors with poor progno-sis, which are composed of intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma and gallbladder cancer. Due to the difficulty of early diagnosis of biliary tract cancers, most patients are diagnosed in the late stage with low surgical resection rates. Moreover, the efficacy of traditional chemotherapy regimens, such as gemcitabine plus cisplatin, is limited. In recent years, the rise of immune checkpoint inhibitors and molecular targeted therapy have provided new treatment options for patients with advanced biliary tract cancers. Based on literature reports and team experiences, the authors discuss the latest research progress in the immunotherapy and molecular targeted therapy of biliary tract cancers, and explore future treatment strategies.
